menu
    • menu
    [{"orgOrder":0,"company":"University of Zurich","sponsor":"Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Alanyl Glutamine","moa":"Amino acid metabolism","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Zurich \/ Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Z\u00fcrich","highestDevelopmentStatusID":"11","companyTruncated":"University of Zurich \/ Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"University of Texas at Austin","sponsor":"Kyowa Hakko Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Alanyl Glutamine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"University of Texas at Austin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas at Austin \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"1","companyTruncated":"University of Texas at Austin \/ Kyowa Hakko Bio"}]

    Find Clinical Drug Pipeline Developments & Deals for Alanyl Glutamine

    Menu

    Alanyl Glutamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Zurich

                            Country arrow
                            CPhI India
                            Not Confirmed

                            University of Zurich

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alanyl Glutamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Sponsor : Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Optimized Therapy in Severe Traumatic Brain Injured Patients

                            Details : Dipeptiven is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Brain Injuries, Traumatic.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 05, 2014

                            Lead Product(s) : Alanyl Glutamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Sponsor : Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Texas at Austin

                            Country arrow
                            CPhI India
                            Not Confirmed

                            University of Texas at Austin

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alanyl Glutamine

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Kyowa Hakko Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Sustamine(TM) on Cycling Time Trial Performance

                            Details : Sustamine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 20, 2012

                            Lead Product(s) : Alanyl Glutamine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Kyowa Hakko Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth